Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR – Free Report) – Equities research analysts at HC Wainwright boosted their Q4 2027 EPS estimates for shares of Arrowhead Pharmaceuticals in a research note issued to investors on Tuesday, May 12th. HC Wainwright analyst P. Trucchio now forecasts that the biotechnology company will earn $0.16 per share for the quarter, up from their prior estimate of $0.13. HC Wainwright currently has a “Buy” rating and a $100.00 target price on the stock. The consensus estimate for Arrowhead Pharmaceuticals’ current full-year earnings is ($3.04) per share.
ARWR has been the topic of a number of other research reports. B. Riley Financial upped their target price on shares of Arrowhead Pharmaceuticals from $61.00 to $101.00 and gave the company a “buy” rating in a research note on Thursday, January 22nd. JPMorgan Chase & Co. began coverage on shares of Arrowhead Pharmaceuticals in a research report on Friday, May 1st. They set an “overweight” rating and a $88.00 price objective for the company. Piper Sandler reaffirmed an “overweight” rating and set a $110.00 price objective (up from $100.00) on shares of Arrowhead Pharmaceuticals in a research report on Tuesday, January 13th. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Arrowhead Pharmaceuticals in a research report on Wednesday, May 6th. Finally, Morgan Stanley raised shares of Arrowhead Pharmaceuticals from an “equal weight” rating to an “overweight” rating and boosted their price objective for the company from $78.00 to $100.00 in a research report on Tuesday, April 21st. One equities research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating and two have assigned a Hold rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $92.44.
Arrowhead Pharmaceuticals Stock Performance
Shares of Arrowhead Pharmaceuticals stock opened at $79.04 on Wednesday. The firm has a market cap of $11.13 billion, a PE ratio of -36.76 and a beta of 1.28. The firm’s 50-day simple moving average is $65.12 and its 200-day simple moving average is $61.17. The company has a debt-to-equity ratio of 1.41, a quick ratio of 6.23 and a current ratio of 6.23. Arrowhead Pharmaceuticals has a 1 year low of $14.30 and a 1 year high of $80.26.
Arrowhead Pharmaceuticals (NASDAQ:ARWR – Get Free Report) last issued its earnings results on Thursday, May 7th. The biotechnology company reported ($0.93) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.10) by $0.17. The business had revenue of $73.74 million for the quarter, compared to analyst estimates of $73.84 million. Arrowhead Pharmaceuticals had a negative net margin of 48.38% and a negative return on equity of 55.09%. The company’s revenue for the quarter was down 86.4% on a year-over-year basis. During the same quarter in the prior year, the business posted $2.75 EPS.
Insider Activity at Arrowhead Pharmaceuticals
In other news, insider James C. Hamilton sold 10,000 shares of the stock in a transaction that occurred on Thursday, April 23rd. The shares were sold at an average price of $75.00, for a total value of $750,000.00. Following the completion of the transaction, the insider directly owned 226,958 shares in the company, valued at $17,021,850. This trade represents a 4.22% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Daniel Joseph Apel sold 13,095 shares of the stock in a transaction that occurred on Wednesday, April 22nd. The shares were sold at an average price of $71.35, for a total transaction of $934,328.25. Following the sale, the chief financial officer directly owned 162,905 shares of the company’s stock, valued at approximately $11,623,271.75. This represents a 7.44% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold 33,095 shares of company stock valued at $2,326,228 over the last quarter. Insiders own 3.60% of the company’s stock.
Institutional Trading of Arrowhead Pharmaceuticals
Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. WCM Investment Management LLC lifted its stake in Arrowhead Pharmaceuticals by 23.5% during the first quarter. WCM Investment Management LLC now owns 171,575 shares of the biotechnology company’s stock valued at $9,891,000 after purchasing an additional 32,670 shares during the last quarter. Dimensional Fund Advisors LP lifted its stake in Arrowhead Pharmaceuticals by 312.8% during the first quarter. Dimensional Fund Advisors LP now owns 608,531 shares of the biotechnology company’s stock valued at $38,150,000 after purchasing an additional 461,119 shares during the last quarter. Parallel Advisors LLC lifted its stake in Arrowhead Pharmaceuticals by 407.1% during the first quarter. Parallel Advisors LLC now owns 1,004 shares of the biotechnology company’s stock valued at $63,000 after purchasing an additional 806 shares during the last quarter. SEB Asset Management AB acquired a new stake in Arrowhead Pharmaceuticals during the first quarter valued at approximately $9,919,000. Finally, California Public Employees Retirement System acquired a new stake in Arrowhead Pharmaceuticals during the first quarter valued at approximately $16,122,000. 62.61% of the stock is owned by institutional investors and hedge funds.
About Arrowhead Pharmaceuticals
Arrowhead Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Since its founding in 2008, Arrowhead has leveraged its proprietary delivery platform—known internally as the Advanced RNAi Compound (ARC) technology—to silence disease-causing genes in patients suffering from genetically defined diseases. The company’s approach aims to offer durable, targeted treatments across a range of therapeutic areas.
The company’s pipeline includes multiple candidates in various stages of development.
Featured Articles
- Five stocks we like better than Arrowhead Pharmaceuticals
- A Real Biggie Deal: Wendy’s Serves Up a Juicy Buyout Arbitrage
- Ally Financial Is Back to Basics—And Investors Are Watching
- Navitas Breaks Out on India Deal, Validating High-Power AI Pivot
- Navy Catalyst Ignites Odysight’s Growth Engine
Receive News & Ratings for Arrowhead Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arrowhead Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
